This includes the development and characterization of cellular and animal models of CTNNB1 syndrome and the advancement of various programs to develop treatments for CTNNB1, including small molecule treatment, RNA-based therapy, AAV9 gene replacement therapy (GRT), and DNA modification techniques. The gene discussed is CTNNB1; the disease is severe intellectual disability-progressive spastic diplegia syndrome.